In a murine model of NSCLC, Kaplanov et al. demonstrated that combination therapy with both anti-IL-1β and anti-PD-1 treatment had a synergistic effect, leading to the complete inhibition of tumor growth for 30 days [82]. This evidence concerns the gene IL1B and non-small cell lung carcinoma.